• Sep 15, 2026

  $288.90-0.40%

  Comparable Hospital & Medical Service Plans companies fell 2.39% on average on the day, with all five names lower [1]. The company's -0.40% decline was in the same direction as its peers but smaller in magnitude [1].

  • 1Peer group

• Sep 14, 2026

  $290.05+3.31%

  Comparable Hospital & Medical Service Plans companies rose 2.23% on average, with four of five names higher [1]. The company's 3.31% gain came alongside this broader move among its peers [1].

  • 1Peer group

• Sep 11, 2026

  $280.76-0.05%

  Shares were little changed, slipping 0.05% [1]. This came even as comparable Hospital & Medical Service Plans companies rose 0.79% on average, with 4 of 5 peers gaining [1].

  • 1Peer group

• Sep 10, 2026

  $280.91+0.99%

  Shares rose 0.99%, a smaller gain than the 1.83% average advance across comparable Hospital & Medical Service Plans companies, four of which rose that day [2]. Seeking Alpha reported that Trump said nearly one million ACA exchange enrollees in 30 federal-run states would receive $500 refunds from surplus user fees [1].

  • 1Seeking Alpha
  • 2Peer group

• Sep 9, 2026

  $278.17+0.85%

  Cigna Group announced it would host an Investor Day on September 30 [1]. Comparable listed companies in Hospital & Medical Service Plans fell 1.17% on average that day, with all five peers declining, while CI's shares rose 0.85%, a move not shared by the cohort [2].

  • 1Pr Newswire
  • 2Peer group

• Sep 8, 2026

  $275.83-2.37%

  Cigna shares fell 2.37%, a steeper decline than the 1.19% average drop among comparable Hospital & Medical Service Plans companies, where three of five names fell and two rose [1].

  • 1Peer group

• Sep 4, 2026

  $282.52-1.31%

  CI shares fell 1.31%, closely matching a decline of 1.28% on average across comparable Hospital & Medical Service Plans companies, all five of which fell that day [1].

  • 1Peer group

Closing prices for CI. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.